Appriss Inc., a leading technology provider for risk assessment and analytics, announced it has acquired NARxCHECK™ from the National Association Boards of Pharmacy Foundation (NABPF) to automate prescription drug abuse assessment and management through patented analytics.
Developed by an emergency room physician and in collaboration with hospital associations, state pharmacy boards, NABPF, an affiliate the National Association of Boards of Pharmacy (NABP), and others, NARxCHECK can quickly identify those patients who may be at heightened risk for misuse of controlled substances.
The non-profit Boards of Pharmacy (NABP) sold its own project, thus converting it into for-profit enterprise, even though it remains a fundamental part of the non-profit’s strategy. This virtually guarantees business for NARxCHECK and a tidy profit for investors.
The technology supports practitioners by accessing patient prescription information from prescription drug monitoring programs (PMP), analyzing the data, and providing a risk-based score to assist practitioners in their health care decision-making.
They are essentially proposing that computers should make decisions about our health care. Even if a doctor has to ultimately decide, when presented with reams of computer selected and compiled documentation supporting a computer-made decision, it would be far too much work to justify overriding the computer’s recommendations.
The acquisition of NARxCHECK (http://www.narxcheck.com) unifies the family of PMP services Appriss provides in partnership with NABP including
- PMP InterConnect – the interstate PMP data sharing service,
- PMP Gateway, a health IT connectivity solution to deliver PMP data to health IT and pharmacy IT systems, and
- NARxCHECK, a risk analytics solution to assess patient risk.
It seems these three newly created companies have successfully inserted themselves into every step of the tangled process that’s been constructed between doctors, patients, and pain relief. It’s disconcerting to know that such private corporations are allowed to look through our medical records.
From the rush of companies getting into the drug-addict witch-hunt business, it’s clear that there’s much money to be made. Sadly, the American tax payer and patients will be expected to shoulder all the additional expense so that profits can be made.
I posted previously about another company that has popped up to “help” doctors: ProtectPainCare. A more accurate name for their business model would be “PreventPainCare”.
NARxCHECK™ (Home Page)
Government & Insurers – Large entities with substantial prescription databases to manage and evaluate will benefit from our Insight product.
Hospitals & Pharmacies – NARXCHECK Plus is a fully automated program for locations that see a high volume of patients and need real-time data quickly recovered.
Private Practices – NARxCHECK Direct provides a patient’s NARxCHECK Scores and NARxCHECK Report along with other patient data via a single sign-on in the provider’s electronic medical record system.
Of course there is no mention of patients, the ones for whom these drugs were created, the ones who so desperately need them. Instead, the whole focus is on how to prevent access to opioid medications.
Pharmacists organizations are aligning themselves with the DEA. Here are some gems from the conference PowerPoint presentation:
Current Status of Prescription Monitoring Programs
- Prescription Monitoring Programs
- PMP InterConnect
- Leveraging technology to increase PMP usage
The presentation includes dozens of slides of a US Map, showing which states have various PMP programs in place, including such gems as:
“States with Statutory Authority to Require Veterinarians to Report to the State PMP”
Another slide shows how Law Enforcement can override HIPPA:
There’s more, but it’s too depressing to post.
(I’m sure whether to thank or curse painkills2 for making me aware of this)